STAXYN
LOE ApproachingNDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jun 2010
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 33m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STAXYN is an orally disintegrating tablet formulation of vardenafil, a phosphodiesterase-5 (PDE-5) inhibitor approved by the FDA in 2010. The drug is indicated for the treatment of erectile dysfunction in adult males. It works by relaxing smooth muscle and increasing blood flow to the penis during sexual stimulation.
LOE Approaching2.1 years to LOE
With only 2.3 years to LOE, the brand team is in maintenance-to-transition mode, likely focused on maximizing remaining revenue rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on STAXYN at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.